372 related articles for article (PubMed ID: 30538305)
21. [Immunotherapy in Epidermal Growth Factor Receptor-mutant
Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):541-545. PubMed ID: 31451147
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].
Basse C; Swalduz A; Levra MG; Girard N; Remon J; Moro-Sibilot D
Bull Cancer; 2020; 107(7-8):779-791. PubMed ID: 32532420
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for lung cancers: here to stay.
Kris MG; Hellmann MD; Chaft JE
Am Soc Clin Oncol Educ Book; 2014; ():e375-80. PubMed ID: 24857127
[TBL] [Abstract][Full Text] [Related]
24. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report.
Bertelli G; Trovato R; Ugel S; Bria E; Milella M; Bronte V; Pilotto S
Clin Lung Cancer; 2019 Jul; 20(4):e514-e516. PubMed ID: 31122866
[No Abstract] [Full Text] [Related]
26. Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer.
Taniguchi Y; Takeda M; Tamiya A; Kasai T; Atagi S
Ann Oncol; 2018 Nov; 29(11):2262-2263. PubMed ID: 30202942
[No Abstract] [Full Text] [Related]
27. Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations.
Taniguchi Y; Tamiya A; Ishii S; Atagi S
Ann Oncol; 2018 May; 29(5):1331-1333. PubMed ID: 29522162
[No Abstract] [Full Text] [Related]
28. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
29. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Puri S; Chatwal M; Gray JE
Expert Rev Respir Med; 2017 Oct; 11(10):791-805. PubMed ID: 28786318
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy combinations emerging in non-small-cell lung cancer.
Chao YL; Pecot CV
Immunotherapy; 2018 Jun; 10(8):627-629. PubMed ID: 29882690
[No Abstract] [Full Text] [Related]
31. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
Gkolfinopoulos S; Mountzios G
Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
[No Abstract] [Full Text] [Related]
32. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
33. [Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial].
Trommer M
Strahlenther Onkol; 2024 Jul; 200(7):646-648. PubMed ID: 38635049
[No Abstract] [Full Text] [Related]
34. Evolving Treatment Options for Lung Cancer.
Morgensztern D; Herbst RS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
[No Abstract] [Full Text] [Related]
35. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
Patel JD; Chmura SJ
Cancer; 2018 Jul; 124(14):2878-2880. PubMed ID: 29906817
[No Abstract] [Full Text] [Related]
36. Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.
Stiles BM; Sepesi B; Broderick SR; Bott MJ
J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1376-1382. PubMed ID: 32763029
[No Abstract] [Full Text] [Related]
37. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
38. Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.
Ricciuti B; Wang X; Awad MM
JAMA Oncol; 2023 Apr; 9(4):570-571. PubMed ID: 36729462
[No Abstract] [Full Text] [Related]
39. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
40. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
